from the complex to interact with factor IXa in the coagulation cascade
1 of 8
Factor VIII concentrate- therapeutic effect
being able to form complex with factor IX means that it can activate factor X and the common pathway of the coagulation cascade
2 of 8
Desmopressin- mechanism of action
Agonist activity at V2 receptors on vascular endothelial cells leads to a rise in intracellular concentrations of cyclic adenosine monophosphate, which in turn induces exocytosis of VWF from its storage sites
3 of 8
Desmopressin- therapeutic effect
Increasing VWF stabilised factor VIII and also promotes platelet aggregation
4 of 8
Tranexamic acid - mechanism of action
competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin also directly inhibits plasmin activity,
5 of 8
Tranexamic acid- therapeutic effect
competitively inhibits the activation of plasminogen to plasmin. and therefore less of the fibrin matrix is degraded
6 of 8
Hydroxyurea/ Hydroxycarbamide- mechanism of action
being able to form complex with factor IX means that it can activate factor X and the common pathway of the coagulation cascade
Back
Factor VIII concentrate- therapeutic effect
Card 3
Front
Agonist activity at V2 receptors on vascular endothelial cells leads to a rise in intracellular concentrations of cyclic adenosine monophosphate, which in turn induces exocytosis of VWF from its storage sites
Back
Card 4
Front
Increasing VWF stabilised factor VIII and also promotes platelet aggregation
Back
Card 5
Front
competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin also directly inhibits plasmin activity,
Comments
No comments have yet been made